Skip to Main Content
Contribute Try STAT+ Today

For Francis deSouza, the CEO of DNA sequencer manufacturer Illumina, the hardest moments of the Covid-19 pandemic are still fresh. He has, he says, been talking to his aunt, who is in her 90s and lives in a village in Goa, India, who is afraid to leave her home.

“She’s confused, and there’s a lot of misinformation out there,  so it’s heartbreaking to watch her go through this and be unable to help from so far away,” deSouza said last week at the STAT Health Tech Summit. “And that story has played out so many times over the last year.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • There are several other companies successful with liquid biopsies and Next-Generation Sequencing. In the past 6-9 months the FDA approved tests developed by Guardant Health (GH), NeoGenomics (NEO) and Foundation One (priv). There will be many more. Illumina deserves credit for SARS-CoV-2 sequencing, and continued work on variants – but it does have competition even if it gets Grail back under its wings.

  • Love this industry!
    Seeking a distributorship contract to help take to market!

Comments are closed.